mailitics

Category: Drug prices

  • STAT+: Moderna’s reset hinges on oncology

    STAT+: Moderna’s reset hinges on oncology Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Seems as though investors are still rewarding sheer weight loss over tolerability in the obesity drug race. The FDA moved at a rapid clip with a new myeloma…

  • STAT+: TrumpRx’s slow start

    STAT+: TrumpRx’s slow start You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays. Mary Talley Bowden, who spent years in an expensive court battle with the Texas Medical Board over her license for…

  • STAT+: FDA warns more telehealth firms about compounded GLP-1s

    STAT+: FDA warns more telehealth firms about compounded GLP-1s Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Moderna is avoiding what would have been a high-profile trial, but will still have to pay up. That and more news below. Let’s…

  • STAT+: A Merck cancer drug to watch

    STAT+: A Merck cancer drug to watch Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning! The impact of President Trump’s “most-favored nation” drug-pricing push can be hard to decipher, but the policy is starting to look less like a slogan and…

  • STAT+: Novo doubles down on oral peptides

    STAT+: Novo doubles down on oral peptides Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. By the time this newsletter sends, I’ll be on a plane headed towards vacation. See you next week! The need-to-know this morning Alkermes CEO Richard…

  • STAT+: Novo reports ‘triple G’ obesity drug study results

    STAT+: Novo reports ‘triple G’ obesity drug study results Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. I hope everyone on the East Coast is staying warm. Let’s get into the news today. How low can obesity drug prices go?…

  • STAT+: Drugmakers lay out their legal arguments against Trump’s drug pricing experiments

    STAT+: Drugmakers lay out their legal arguments against Trump’s drug pricing experiments WASHINGTON — The pharmaceutical and biotech industries are pushing back against two Trump administration proposals that would test plans to lower drug prices in Medicare by aligning them with the prices paid in other rich countries.  Their comments preview arguments that they might…

  • STAT+: Novo’s next-gen obesity drug stumbles in Lilly comparison study

    STAT+: Novo’s next-gen obesity drug stumbles in Lilly comparison study Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. We’ve got some big acquisition news today, and also some politics — specifically a look at how pharma lobbyists, who have longed considered the…

  • STAT+: Element Biosciences launches table-top sequencer capable of $100 genome

    STAT+: Element Biosciences launches table-top sequencer capable of $100 genome Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Grail’s Galleri blood test just failed a make-or-break NHS trial, missing its primary endpoint and reviving the uncomfortable question: Does earlier detection actually change…

  • STAT+: Psilocybin data could be good enough for approval

    STAT+: Psilocybin data could be good enough for approval Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good day! Today: A look at growing GLP-1 competition in China, a drug reviewed as part of the FDA’s shiny new fast-track voucher hits a roadblock,…

  • STAT+: Pediatricians confront HHS in vaccine showdown

    STAT+: Pediatricians confront HHS in vaccine showdown Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. The FDA’s surprise refusal to even review Moderna’s mRNA flu vaccine is sending a chill through biotech: Companies are openly wondering whether the regulatory goalposts are shifting…

  • STAT+: A change at the top of Sanofi

    STAT+: A change at the top of Sanofi Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Vinay Prasad is tightening the screws at the FDA, overruling staff and signaling a tougher stance on vaccines and gene therapies — which, as Adam Feuerstein…

  • STAT+: TrumpRx: Hype or real savings?

    STAT+: TrumpRx: Hype or real savings? You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays. Did you snack on HHS-approved MAHA-mole while shaking to Bad Bunny’s Spanish-language celebration of Puerto Rican and Latin…

  • STAT+: Hims faces mounting regulatory pressure

    STAT+: Hims faces mounting regulatory pressure Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning! Hope you enjoyed yesterday’s Bad Bunny performance. My son’s take on the Super Bowl: “Why would anyone want to watch something so boring?”  Today, we get…

  • STAT+: TrumpRx claims to offer the lowest prices. But many drugs have cheaper generics

    STAT+: TrumpRx claims to offer the lowest prices. But many drugs have cheaper generics WASHINGTON — President Trump said the administration’s new TrumpRx website will offer the cheapest prices in the world for 43 brand-name drugs, and counting. But about half of them are already available as generics, usually for much less. The website is…

  • STAT+: White House looks for more drug pricing deals to add to TrumpRx

    STAT+: White House looks for more drug pricing deals to add to TrumpRx WASHINGTON — After striking 16 deals with pharmaceutical giants and launching a direct-to-consumer drug purchasing platform, the Trump administration is looking to expand its efforts to lower drug  prices to more companies.  Federal officials on Thursday unveiled the administration’s TrumpRx drug purchasing…

  • What to know about TrumpRx, the Trump administration’s prescription drug platform

    What to know about TrumpRx, the Trump administration’s prescription drug platform President Trump on Thursday night is planning to announce the launch of TrumpRx, the website that he and his aides have touted for months as a platform aimed at lowering prescription drug prices.  The website, which uses technology from health care company GoodRx, is…

  • STAT+: Pfizer unveils data on Metsera drug

    STAT+: Pfizer unveils data on Metsera drug Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Did Pfizer overpay for the obesity biotech Metsera? It’s probably still too early to tell, but we have some new data this morning. The need-to-know this…

  • STAT+: AstraZeneca looks to China for obesity drug candidates 

    STAT+: AstraZeneca looks to China for obesity drug candidates  Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Oh, hi. Today, we discuss delays in the launch of TrumpRx. Also, Sanofi is deprioritizing its mRNA flu vaccine.  The need-to-know this morning Regeneron Pharmaceuticals…

  • The high stakes for Huntington’s patients

    The high stakes for Huntington’s patients Biotech company UniQure is set to meet with the Food and Drug Administration to discuss the path forward for its gene therapy for Huntington’s disease, and the outcome could be potentially devastating for patients. That’s what patient advocate Lauren Holder says on the latest episode of “The Readout LOUD,”…

  • STAT+: States are the next vaccine battleground

    STAT+: States are the next vaccine battleground You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays. I’d call it a xeet-down, but I can’t tell who won this heated exchange on X between…

  • STAT+: Launch of Wegovy pill looks to be going strong so far

    STAT+: Launch of Wegovy pill looks to be going strong so far Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning! Today, we see a new synthetic biology startup, backed by Frances Arnold and Bob Langer. Plus, it’s still early, but Novo…

  • STAT+: Insurers blame drugmakers, hospitals for high prices

    STAT+: Insurers blame drugmakers, hospitals for high prices Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning. Today, we see insurers telling Congress that hospital and drugmakers are to blame for health care pricing issues, and read about ways in which some drug…

  • STAT+: Novo strikes deal for diabetes cell therapies

    STAT+: Novo strikes deal for diabetes cell therapies Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We’re breaking down some of the key parts of a sweeping new health care bill today. The need-to-know this morning Johnson & Johnson kicked…

  • STAT+: FDA delays reviews for two drugs in new voucher program

    STAT+: FDA delays reviews for two drugs in new voucher program Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello hello! Hope you survived JPM week and are now recuperating with some electrolytes and a sleep mask. (But don’t forget our virtual…

  • STAT+: Trump releases health care plan amid pressure over affordability

    STAT+: Trump releases health care plan amid pressure over affordability WASHINGTON — President Trump on Thursday released a hodgepodge of health care policies that would create new price-control power over pharmaceutical companies, but that otherwise wouldn’t fundamentally overhaul America’s existing system, as he faces mounting pressure to address the cost of insurance and care. The…

  • STAT+: Former NIH genomics director Eric Green to join Illumina as CMO

    STAT+: Former NIH genomics director Eric Green to join Illumina as CMO Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. The Readout heads to the J.P. Morgan Healthcare Conference next week, which means it will hit your inboxes in the afternoon instead…

  • STAT+: China expected to soon surpass U.S. in bio innovation

    STAT+: China expected to soon surpass U.S. in bio innovation Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. It’s an exciting week not only for biotech M&A, but also for my city (Chicago) as we gear up for our big game…

  • STAT+: Insilico inks cancer drug deal with Servier after IPO

    STAT+: Insilico inks cancer drug deal with Servier after IPO Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Welcome back and happy new year! We have plenty of fresh coverage to start the week. We can also report that our upcoming STAT@JPM…

  • STAT+: Three major health care policy issues to watch in 2026

    STAT+: Three major health care policy issues to watch in 2026 WASHINGTON — Health care figured prominently in the first year of President Trump’s second term, and it’ll likely play an even bigger role leading up to the 2026 midterm elections.  The shift back to health care politics has been somewhat surprising. Although Republicans were…

  • STAT+: Trump moves to require lower drug prices in Medicare

    STAT+: Trump moves to require lower drug prices in Medicare You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays. The NIH director did the Pete & Bobby fitness challenge, but I didn’t see…

  • STAT+: Major pharma companies may avoid Medicare experiments’ forced price cuts

    STAT+: Major pharma companies may avoid Medicare experiments’ forced price cuts Many of the largest drugmakers may be exempt from Medicare pilot programs intended to force them to lower some of their prices, potentially undermining the effort and depriving American patients of cheaper drugs. Several of the 14 pharmaceutical companies that have struck individual drug-pricing…

  • STAT+: Pharmaceutical industry evades drug price transparency, again

    STAT+: Pharmaceutical industry evades drug price transparency, again Drug manufacturers and pharmacy benefit managers received a holiday gift from President Trump on Friday: They still will not have to publicly post the actual prices of prescription drugs, more than five years after federal law required them to do so. Net drug prices — the amounts…

  • STAT+: Trump administration proposes Medicare pilots to lower drug prices on par with peer countries

    STAT+: Trump administration proposes Medicare pilots to lower drug prices on par with peer countries WASHINGTON — The Trump administration proposed two Medicare pilot programs to reduce prices for branded drugs bought at pharmacy counters and administered in doctor offices. If the administration moves forward, the programs could slash Medicare spending on prescription drugs by…

  • STAT+: More drugmakers set to sign pricing deals with Trump on Friday

    STAT+: More drugmakers set to sign pricing deals with Trump on Friday WASHINGTON — Several drugmakers are expected to sign pricing agreements with the Trump administration on Friday, according to four people familiar with the plans, who were not authorized to speak publicly. The agreements would be the latest in a series of deals in…

  • STAT+: FDA initiates priority voucher for J&J’s ‘Tec-Dara’ combo

    STAT+: FDA initiates priority voucher for J&J’s ‘Tec-Dara’ combo Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Apparently the drunk raccoon I mentioned a few weeks ago is a repeat offender.  Onto the biotech news today. Continue to STAT+ to read the…

  • STAT+: Sobi bets big on next-gen gout drug

    STAT+: Sobi bets big on next-gen gout drug Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning. Today, we discuss the implications of a child’s tragic death after receiving a brain-focused gene therapy, hear Siddhartha Mukherjee opine on why the next frontier in…

  • STAT+: Terns leukemia drug could succeed Novartis blockbuster

    STAT+: Terns leukemia drug could succeed Novartis blockbuster Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today we discuss why comparing U.S. vaccine policy to Europe’s is a red herring, why the revolving door at the FDA between government and industry needs modernized…

  • STAT+: Early update shows Wave’s RNA drug cut visceral fat

    STAT+: Early update shows Wave’s RNA drug cut visceral fat Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning! With STAT reporting from ASH this year, we have some stories in the blood space. Also, a potential Dupixent competitor is in the…

  • STAT+: A drug that was ‘engineered with AI’ enters Phase 3 testing

    STAT+: A drug that was ‘engineered with AI’ enters Phase 3 testing Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. My colleagues will be in Orlando later this week for the American Society of Hematology meeting. Sign up for their newsletter…

  • STAT+: Sarepta cleared to test new safety regimen for Duchenne drug

    STAT+: Sarepta cleared to test new safety regimen for Duchenne drug Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We discuss some big news that the Trump administration dropped last night. And we’ll be taking a break this Thursday and Friday. We’ll…

  • STAT+: Lilly hits trillion-dollar valuation as GLP-1 era peaks

    STAT+: Lilly hits trillion-dollar valuation as GLP-1 era peaks Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning! We’re closing in on CMS’s deadline for 2027 Medicare-negotiated drug prices. Plus, we see a break from precedent in how the FDA selects priority review…

  • STAT+: Recursion seeks to deliver results, and a VC sees a wave of M&A coming

    STAT+: Recursion seeks to deliver results, and a VC sees a wave of M&A coming Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We’ve got some spicy comments from Mark Cuban, and a pair of biotech Q&As. Let’s get to…

  • STAT+: Pfizer closes $10 billion Metsera deal

    STAT+: Pfizer closes $10 billion Metsera deal Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning! If you’re still wondering “What the heck happened with Moderna?” the latest episode of the video series STATus Report spells it out quite nicely. Also, a KFF…

  • STAT+: Makary, Prasad outline pathway for bespoke gene therapy

    STAT+: Makary, Prasad outline pathway for bespoke gene therapy Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning. Today, we learn AbbVie has ended its partnership with Calico, the FDA outlines how bespoke gene-editing treatments can make it through the regulatory pipeline,…

  • STAT+: Why is Eli Lilly worth nearly $1 trillion?

    STAT+: Why is Eli Lilly worth nearly $1 trillion? Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We’ve got big FDA news to get into today — let’s get straight into it. FDA names Richard Pazdur as top drug regulator   The…

  • STAT+: Chinese government’s support for biotech fuels huge rally

    STAT+: Chinese government’s support for biotech fuels huge rally Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, we just had our first snow of the season in Chicago, I just ordered a pie for Thanksgiving, and I’m still in denial that…

  • STAT+: States might not get cheaper drugs in Trump’s most-favored nation Medicaid pilot program

    STAT+: States might not get cheaper drugs in Trump’s most-favored nation Medicaid pilot program WASHINGTON — When President Trump announced the administration’s deal to cut prices for weight-loss drugs, he proclaimed that “you will pay the lowest price anywhere in the world.” But state Medicaid programs might already be getting lower prices, according to a research…

  • STAT+: Seven burning questions about Trump’s big deal for cheaper weight loss drugs

    STAT+: Seven burning questions about Trump’s big deal for cheaper weight loss drugs WASHINGTON — The Trump administration’s deal to expand access to and lower the cost of weight loss drugs has left industry leaders, public health experts, and patients with a host of open questions. The administration’s agreements with Eli Lilly and Novo Nordisk…

  • STAT+: Kennedy, a longtime pharma critic, embraces Trump deal to expand access to obesity drugs

    STAT+: Kennedy, a longtime pharma critic, embraces Trump deal to expand access to obesity drugs WASHINGTON — Health Secretary Robert F. Kennedy Jr. was uncharacteristically chummy with pharma executives at the White House on Thursday as he cheered the Trump administration’s plan for lowering obesity medication prices. Kennedy has railed against drugmakers in the past, and…

  • STAT+: Pfizer’s view on the Metsera bidding war

    STAT+: Pfizer’s view on the Metsera bidding war Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We’re hosting a virtual event tomorrow about the rise and unraveling of Moderna. My colleagues Jason Mast and Damian Garde will be there to talk about…

  • STAT+: Scandal and controversy take toll on FDA credibility

    STAT+: Scandal and controversy take toll on FDA credibility Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We’ve got another busy week of earnings — Pfizer reported this morning and Novo Nordisk will be reporting tomorrow. We’ll be watching for any…

  • STAT+: Trump administration nears deals for cheaper weight loss drugs with Novo Nordisk, Eli Lilly

    STAT+: Trump administration nears deals for cheaper weight loss drugs with Novo Nordisk, Eli Lilly WASHINGTON — The Trump administration is nearing deals with Eli Lilly and Novo Nordisk to lower the prices of their weight loss drugs and expand access to them, people familiar with the talks told STAT. The companies have been close to…

  • STAT+: Alnylam raises guidance as sales of heart drug match expectations

    STAT+: Alnylam raises guidance as sales of heart drug match expectations Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning! Today, we have a deep probe into Moderna’s travails from STAT’s tireless Jason Mast. Also, a pharma bidding war, thoughts on psychedelic regulation,…

  • STAT+: Cigna stock nosedives on news that ending PBM rebates will lower that segment’s profit

    STAT+: Cigna stock nosedives on news that ending PBM rebates will lower that segment’s profit The stock market pummeled Cigna on Thursday after the company’s leaders revealed that their new plan to ditch pharmacy benefit rebates will lower that segment’s profit in the coming years. By midmorning, the company’s stock had plunged more than 15%. …

  • STAT+: FDA moves to ease path for biosimilars as Trump seeks to cut drug costs

    STAT+: FDA moves to ease path for biosimilars as Trump seeks to cut drug costs WASHINGTON — The Trump administration announced a draft framework Wednesday that officials say will speed cheaper versions of biologic drugs to market with the aim of making medicine more affordable and accessible for patients. The framework will shorten the path…

  • STAT+: Natera, known for spotting cancer recurrence, wades into early detection

    STAT+: Natera, known for spotting cancer recurrence, wades into early detection Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. It seems everyone I know has been getting sick lately — hope you are all taking care of yourselves! Onto the news…

  • STAT+: Ro wants to measure ‘food noise’ in obesity care

    STAT+: Ro wants to measure ‘food noise’ in obesity care Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, you’ve made it Friday! We’ve got some more news to get through before heading into the weekend. FDA delivers split decision on…

  • STAT+: How the first nine drug companies won priority review vouchers from Marty Makary’s FDA

    STAT+: How the first nine drug companies won priority review vouchers from Marty Makary’s FDA WASHINGTON — Commissioner Marty Makary wants the Food and Drug Administration to move more quickly. The launch of a new priority review voucher program in June was no exception.  The agency promised winners a one- to two-month review of their drug…

  • STAT+: DeSantis downplays importance of health insurance as the government shutdown drags on

    STAT+: DeSantis downplays importance of health insurance as the government shutdown drags on You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays. You might have noticed that the subject line of Tuesday’s newsletter…

  • STAT+: Trump’s IVF deal spurs hopes — and adjustments — across fertility sector

    STAT+: Trump’s IVF deal spurs hopes — and adjustments — across fertility sector WASHINGTON — The Trump administration’s push to make in vitro fertilization more affordable is changing the outlook and offerings in the fertility sector, even as some details of its policies remain confidential and others have yet to be released. The administration’s changes…

  • STAT+: CVS Caremark tells AIDS activists Gilead needs to lower the price of its new HIV drug to get on formularies

    STAT+: CVS Caremark tells AIDS activists Gilead needs to lower the price of its new HIV drug to get on formularies For the past three months, CVS Caremark has resisted adding a new Gilead Sciences HIV prevention drug to its formularies, repeatedly explaining there are “clinical, financial, and regulatory considerations” that must be reviewed before…

  • STAT+: Gilead agrees not to raise prices on HIV medicines for state AIDS drug programs

    STAT+: Gilead agrees not to raise prices on HIV medicines for state AIDS drug programs After months of tense negotiations, Gilead Sciences has agreed not to boost prices next year for HIV medicines that are sold to state AIDS Drug Assistance Programs, an outcome that lessens the financial strains for agencies that are relied on…

  • Trump announces plan to expand fertility treatment coverage alongside latest pharma deal

    Trump announces plan to expand fertility treatment coverage alongside latest pharma deal The Trump administration has struck a deal with EMD Serono to lower drug prices — part of a larger push from the administration to expand coverage and improve affordability for fertility services, officials announced at the White House on Thursday. The administration’s plan…

  • STAT+: J&J reportedly in talks to buy Protagonist

    STAT+: J&J reportedly in talks to buy Protagonist Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. My colleagues were hard at work throughout the weekend reporting on major firings across the CDC. We’ve also got a ton of biopharma news…

  • STAT+: AstraZeneca strikes drug pricing deal with Trump

    STAT+: AstraZeneca strikes drug pricing deal with Trump WASHINGTON — President Trump on Friday said he struck a drug pricing deal with AstraZeneca aimed at fulfilling his plan to bring U.S. drug prices in line with what other countries pay, the second agreement after Pfizer’s last week. Similar to Pfizer’s deal, the British pharma company…

  • STAT+: Roche suffers setback as court allows generic version of its rare disease drug to be sold in India

    STAT+: Roche suffers setback as court allows generic version of its rare disease drug to be sold in India In the latest tussle over access to medicines, an Indian court has upheld a ruling that found it would be in the public interest to allow a generic company to sell a lower-cost version of a…

  • STAT+: Billionaire-backed VC firm launches, led by former Flagship associate

    STAT+: Billionaire-backed VC firm launches, led by former Flagship associate Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. At the start of this week, my editor said the news flow was looking slow. He’s jinxed us yet again. Let’s get…

  • STAT+: Orca submits T cell therapy for FDA approval

    STAT+: Orca submits T cell therapy for FDA approval Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. We’ve got some exciting news of our own this morning: the return of Damian Garde, who once authored this very newsletter and who is coming…

  • STAT+: TCGX closes $1.3 billion fund amid investor surge

    STAT+: TCGX closes $1.3 billion fund amid investor surge Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Today, we talk about the big regulatory changes afoot in Europe, how telehealth upended the drug market, and more. The need-to-know this morning …

  • STAT+: A second generic version of the abortion pill mifepristone approved by FDA

    STAT+: A second generic version of the abortion pill mifepristone approved by FDA Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hullo! Today, we talk about Amgen’s positive new PCSK9 data, learn more about the new NIH office meant to reduce reliance…

  • A pharma C-suite shakeup and Trump’s deal with Pfizer

    A pharma C-suite shakeup and Trump’s deal with Pfizer How will we look back on Emma Walmsley’s tenure as GSK’s CEO? Why did one of the FDA’s top drug officials call out an obscure lupus drug on LinkedIn? And will we ever stop talking about the pharma patent cliff? We discuss all that and more…

  • STAT+: Which biotechs are affected by the government shutdown?

    STAT+: Which biotechs are affected by the government shutdown? Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. I can’t believe it either, but we’re in the fourth quarter of the year. We’ve got a guide for you on the key…

  • STAT+: Veru update shows FDA still values weight loss over body composition

    STAT+: Veru update shows FDA still values weight loss over body composition Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We’ve got big news on a gene therapy for Huntington’s disease, so let’s get straight to it. Uniqure hails ‘groundbreaking’…

  • STAT+: Doctors are more tied to pharma as trust erodes

    STAT+: Doctors are more tied to pharma as trust erodes Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning. Today, we read about a big acquisition fueled by obesity, doctors shifting their views on biopharma marketing, see a rare disease drug win approval after…

  • STAT+: U.S. pressures U.K. as pharma pauses investments there

    STAT+: U.S. pressures U.K. as pharma pauses investments there Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning. Today, we see moves to potentially dismantle FDA ad comms, see the U.S. pressuring the U.K. over its stringent drug-pricing policy, and more.  The…

  • STAT+: Pig kidneys to enter FDA-backed human trial next year

    STAT+: Pig kidneys to enter FDA-backed human trial next year Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello there. Today, we learn the FDA is advancing a trial for gene-edited pig organs in humans, see geographical discrepancies in lung cancer trial…

  • STAT+: Gilead wants state AIDS drug programs to pay significant price hikes for HIV meds

    STAT+: Gilead wants state AIDS drug programs to pay significant price hikes for HIV meds Gilead Sciences, the largest maker of HIV medicines, is seeking to boost prices significantly for several treatments that are widely distributed by state AIDS Drug Assistance Programs. And the move is adding to financial uncertainty for the programs on top…

  • STAT+: Trump pressures drugmakers amid CDC turmoil

    STAT+: Trump pressures drugmakers amid CDC turmoil Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Welcome back from the holiday weekend. Today we have some candor in ALL CAPS from Trump on Covid vaccines, glowy data from Ionis that could lead to…

  • STAT+: Third Rock tops STAT’s annual VC ranking

    STAT+: Third Rock tops STAT’s annual VC ranking Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. My colleague Allison DeAngelis has been working for months on our annual VC rankings report. Read on for what she found. Third Rock tops…

  • STAT+: Supreme Court lets Trump slash NIH research funds

    STAT+: Supreme Court lets Trump slash NIH research funds Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. The Supreme Court is allowing the Trump administration to cut $783 million in research grants tied to DEI work. Also, STAT just unveiled…

  • STAT+: Was the reaction to Viking’s oral data overblown?

    STAT+: Was the reaction to Viking’s oral data overblown? Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We learned yesterday that Walmart has recalled some of its frozen shrimp after the FDA warned that they may have been contaminated with…

  • STAT+: FDA delays decision on Regenxbio gene therapy

    STAT+: FDA delays decision on Regenxbio gene therapy Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Today we look at what some people in the industry are calling a “pharm to table” trend. Read on to learn more about it.…

  • STAT+: Who are the richest people in health care right now?

    STAT+: Who are the richest people in health care right now? Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning. Today, we examine the plush pay packages of health care’s top CEOs in 2024. Also, we discuss Stealth BioTherapeutics’ efforts to rally…

  • STAT+: Eli Lilly says it will hike list prices for drugs abroad. Now what?

    STAT+: Eli Lilly says it will hike list prices for drugs abroad. Now what? Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning. Today, we see march-in rights return to the headlines, ponder how Eli Lilly’s plan to hike list prices in Europe…

  • STAT+: Stoke Therapeutics release new data on Dravet syndrome drug

    STAT+: Stoke Therapeutics release new data on Dravet syndrome drug Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. As AI becomes more widely used in health care, could it actually lead doctors to lose some of their skills? One new…

  • STAT+: Trump demands drugmakers slash U.S. price now

    STAT+: Trump demands drugmakers slash U.S. price now Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, and happy birthday to me! Today, we see the Senate Appropriations Committee look to increase NIH funding, despite the Trump administration’s request to slash…

  • STAT+: U.S. judge blocks first-in-the-nation law barring companies from owning PBMs and pharmacies in Arkansas

    STAT+: U.S. judge blocks first-in-the-nation law barring companies from owning PBMs and pharmacies in Arkansas In a closely watched case, a U.S. federal court judge has temporarily blocked a first-in-the-nation law that would prohibit companies that own pharmacy benefit managers from also operating both retail and mail-order pharmacies in Arkansas. The state law is designed…

  • STAT+: FDA panel stirs backlash for SSRI use during pregnancy

    STAT+: FDA panel stirs backlash for SSRI use during pregnancy Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning. Today, we discuss how Duchenne patients and their families are responding to the shelving of Sarepta Therapeutics’ gene therapy, see an FDA panel…

  • STAT+: FDA opens applications for new voucher program 

    STAT+: FDA opens applications for new voucher program  Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We’ve got more developments with Sarepta today. My colleagues got exclusive comments from a senior FDA official — read on for what the official said.…

  • Opinion: STAT readers weigh in on marijuana-related vomiting, drug prices, and more

    Opinion: STAT readers weigh in on marijuana-related vomiting, drug prices, and more First Opinion is STAT’s platform for interesting, illuminating, and provocative articles about the life sciences writ large, written by biotech insiders, health care workers, researchers, and others. To encourage robust, good-faith discussion about issues raised in First Opinion essays, STAT publishes selected Letters…

  • STAT+: Questions about the FDA’s ‘radical transparency’ efforts

    STAT+: Questions about the FDA’s ‘radical transparency’ efforts Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Happy Friday. Today, we talk about the stem cell fire sale at CIRM, and about the FDA’s move to release a limited batch of complete response letters. FDA…

  • STAT+: Brawl over Eylea gets biosimilar industry’s attention

    STAT+: Brawl over Eylea gets biosimilar industry’s attention Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello! Today, we talk about a cool experimental enzyme therapy, observe more patent maneuvers over Eylea, and see an ‘underdog’ startup get a huge seed round to…

  • STAT+: Khosla Ventures sets sights on $4 billion in new funds

    STAT+: Khosla Ventures sets sights on $4 billion in new funds Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello, friends! We’re back. Hope you are having a delightful summer (or winter, I suppose, depending on your hemisphere). Today, we talk about morale…

  • STAT+: Vertex stem cell therapy spurs insulin independence

    STAT+: Vertex stem cell therapy spurs insulin independence Good morning! Today, we get deeper into the ousting of Nicole Verdun at the FDA, see promise from Vertex’s cell therapy for diabetes, and unpack the story of developing the newly approved Gilead PrEP drug lenacapivir. The need-to-know this morning Novo Nordisk terminated its marketing relationship with…

  • STAT+: More universities open to private equity deals, and emerging companies turn to new targets

    STAT+: More universities open to private equity deals, and emerging companies turn to new targets This is the online version of our BIO 2025 newsletter. Get more BIO updates directly to your inbox by signing up here, and sign up for our morning biotech news roundup newsletter here. Hello all, I have a fresh double…